查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566904

脂質奈米顆粒市場：按類型、應用和最終用戶分類：2024-2033 年全球機會分析和產業預測

Lipid Nanoparticles Market By Type , By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 220 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，全球脂質奈米顆粒市場價值為9億美元，預計2024年至2033年複合年成長率為13.1%，到2033年將達到31億美元。

脂質奈米顆粒（LNP）是直徑在10至1000奈米之間的奈米級顆粒，主要由脂質組成。它們旨在封裝藥物、疫苗和遺傳物質等治療劑，保護它們免受分解並增強藥物傳遞和功效。 LNP 可以模仿生物膜的結構，使其具有生物相容性，並且能夠有效地與細胞相互作用並穿透細胞。脂質組合物通常包括磷脂質、膽固醇和其他脂質分子，有助於穩定奈米顆粒結構並控制包封物質的釋放。

脂質奈米顆粒市場的成長是由癌症、糖尿病、心血管疾病、神經病變等慢性疾病盛行率上升以及對先進藥物傳輸系統的需求迅速成長所推動的。這些疾病通常需要長期使用藥物治療，而以傳統方式給藥時會產生嚴重的副作用。 LNP 為標靶和持續遞送治療藥物提供了一種有前途的替代方案，可減少全身副作用並提高患者的依從性。例如，在腫瘤學中，LNP 用於將化療藥物直接遞送至癌細胞，從而最大限度地減少對健康組織的損害。

然而，基於LNP的製劑的生產和開拓在製造過程中涉及高科技和嚴格的品管措施，以確保奈米顆粒的穩定性和功效，導致高成本，導致市場增加，限制了市場。相反，奈米技術的進步促進了脂質奈米顆粒的開發，其穩定性更高，具有靶向遞送和控釋功能。這開闢了藥物輸送的新途徑，從而實現更有效和高效的治療性介入。例如，2022年1月，輝瑞和Acuitas Therapeutics（一家專注於開發脂質奈米顆粒（LNP）遞送系統的公司，該系統可實現基於傳訊RNA（mRNA）的治療）宣布，輝瑞和Acuitas Therapeutics（一家專注於開發脂質奈米顆粒的公司） LNP）遞送系統能夠實現基於信使 RNA (mRNA) 的治療，輝瑞宣布已簽訂開發和選擇協議，可選擇非獨家許可 Acuitas 的 LNP 技術用於最多 10 個靶點。

分部概覽

脂質奈米顆粒市場的分析分為類型、應用、最終用戶和區域。依類型分類，市場分為固體脂質奈米顆粒、奈米結構脂質載體等。依用途分為治療類和研究類。依最終用戶分類，可分為製藥/生技公司、學術/研究機構等。從區域來看，我們對北美、歐洲、亞太地區和拉丁美洲地區進行了分析。

主要發現

按類型分類，固體奈米顆粒細分市場在 2023 年佔據最高市場佔有率。

按應用分類，治療藥物領域在 2023 年佔據最大市場。

從最終用戶來看，製藥和生技公司將在 2023 年成為市場的最大股東。

按地區分類，北美在 2023 年主導脂質奈米顆粒市場。

競爭場景

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • 主要參與者的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 主要投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章脂質奈米顆粒市場：依類型

  • 市場概況
  • 固體脂質奈米粒
  • 奈米結構脂質載體
  • 其他

第5章脂質奈米顆粒市場：依應用分類

  • 市場概況
  • 治療藥物
  • 研究

第6章脂質奈米顆粒市場：依最終用戶分類

  • 市場概況
  • 製藥和生物技術公司
  • 學術/研究機構
  • 其他

第7章脂質奈米顆粒市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國脂質奈米顆粒市場
    • 加拿大脂質奈米顆粒市場
    • 墨西哥脂質奈米顆粒市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國脂質奈米顆粒市場
    • 法國脂質奈米顆粒市場
    • 英國脂質奈米顆粒市場
    • 義大利脂質奈米顆粒市場
    • 西班牙脂質奈米顆粒市場
    • 其他歐洲國家脂質奈米顆粒市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本脂質奈米粒子市場
    • 中國脂質奈米粒市場
    • 印度脂質奈米顆粒市場
    • 澳洲脂質奈米顆粒市場
    • 韓國脂質奈米顆粒市場
    • 其他亞太脂質奈米顆粒市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西脂質奈米顆粒市場
    • 沙烏地阿拉伯脂質奈米顆粒市場
    • 南非脂質奈米顆粒市場
    • 其他拉丁美洲/中東/非洲脂質奈米顆粒市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • ABP Biosciences, LLC.
  • Merck KGaA
  • Cytiva
  • CD Bioparticles
  • CordenPharma
  • Precigenome LLC.
  • Beam Therapeutics
  • Acuitas Therapeutics.
  • Helix Biotech, Inc.
  • Genevant Sciences Corporation
簡介目錄
Product Code: A323703

The global lipid nanoparticles market was valued at $0.9 billion in 2023, and is projected to reach $3.1 billion by 2033, growing at a CAGR of 13.1% from 2024 to 2033

Lipid nanoparticles (LNPs) are nanoscale particles ranging from 10 to 1000 nanometers in diameter, primarily composed of lipids. They are designed to encapsulate therapeutic agents such as drugs, vaccines, and genetic materials, protecting them from degradation and enhancing their delivery and efficacy. LNPs can mimic the structure of biological membranes, making them biocompatible and capable of efficiently interacting with and penetrating cells. Their lipid composition typically includes phospholipids, cholesterol, and other lipid molecules that aid in stabilizing the nanoparticle structure and controlling the release of the encapsulated cargo.

The growth of the lipid nanoparticles market is driven by rise in the prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and neurological disorders, and surge in demand for advanced drug delivery systems. These conditions often require long-term treatment with drugs that have severe side effects when administered through traditional methods. LNPs offer a promising alternative by enabling targeted and sustained delivery of therapeutic agents, thereby reducing systemic side effects and improving patient compliance. In oncology, for instance, LNPs are used to deliver chemotherapeutic agents directly to tumor cells, minimizing damage to healthy tissues.

However, high cost associated with the production and development of LNP-based formulations, as the manufacturing process involves sophisticated technology and stringent quality control measures to ensure the stability and efficacy of the nanoparticles, leads to increased production costs which limit the market growth. On the contrary, advances in nanotechnology facilitated the development of lipid nanoparticles with enhanced stability, targeted delivery, and controlled release properties. This opened new avenues for drug delivery, allowing for more effective and efficient therapeutic interventions. For instance, in January 2022, Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA) -based therapeutics announced that they had entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.

Segmentation Overview

The lipid nanoparticles market analysis is segmented into type, application, end user, and region. Depending on type, the market is categorized into solid lipid nanoparticles, nanostructured lipid carriers, and others. By application, it is bifurcated into therapeutics and research. As per end user, the market is classified into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the solid lipid nanoparticles segment held the highest market share in 2023.

Depending on the application, the therapeutics segment accounted for maximum share in the market in 2023.

According to end user, the pharmaceutical & biotechnology companies have been the largest shareholder in the market in 2023.

Region wise, North America dominated the lipid nanoparticles market in 2023.

Competitive Scenario

The major players operating in the lipid nanoparticles market include ABP Biosciences, LLC., Merck KGaA, Cytiva, CD Bioparticles, CordenPharma, Precigenome LLC., Beam Therapeutics, Acuitas Therapeutics, GENEVANT SCIENCES CORPORATION, and Helix Biotech, Inc. Other players in lipid nanoparticles market includes Arbutus Biopharma, and Croda International Plc. These players have adopted several strategies, including mergers & acquisitions, collaborations, product innovation & diversification, and partnerships, to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers
  • Others

By Application

  • Therapeutics
  • Research

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • ABP Biosciences, LLC.
    • Merck KGaA
    • Cytiva
    • CD Bioparticles
    • CordenPharma
    • Precigenome LLC.
    • Beam Therapeutics
    • Acuitas Therapeutics.
    • Helix Biotech, Inc.
    • Genevant Sciences Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: LIPID NANOPARTICLES MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Solid Lipid Nanoparticles
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Nanostructured Lipid Carriers
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: LIPID NANOPARTICLES MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Therapeutics
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Research
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: LIPID NANOPARTICLES MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Pharmaceutical And Biotechnology Companies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Academic And Research Institutes
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: LIPID NANOPARTICLES MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Lipid Nanoparticles Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Lipid Nanoparticles Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Lipid Nanoparticles Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Lipid Nanoparticles Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Lipid Nanoparticles Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Lipid Nanoparticles Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Lipid Nanoparticles Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Lipid Nanoparticles Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Lipid Nanoparticles Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Lipid Nanoparticles Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Lipid Nanoparticles Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Lipid Nanoparticles Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. Australia Lipid Nanoparticles Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Lipid Nanoparticles Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Lipid Nanoparticles Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Lipid Nanoparticles Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Lipid Nanoparticles Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Lipid Nanoparticles Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Lipid Nanoparticles Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. ABP Biosciences, LLC.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Merck KGaA
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Cytiva
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. CD Bioparticles
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. CordenPharma
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Precigenome LLC.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Beam Therapeutics
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Acuitas Therapeutics.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Helix Biotech, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Genevant Sciences Corporation
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments